Insulin (medication)

Insulin Drugs Global Market Report 2023

Retrieved on: 
Monday, February 20, 2023

The global insulin drugs market will grow from $32.83 billion in 2022 to $36.50 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%.

Key Points: 
  • The global insulin drugs market will grow from $32.83 billion in 2022 to $36.50 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%.
  • The regions covered in the insulin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The insulin drugs market research report is one of a series of new reports that provides insulin drugs market statistics, including insulin drugs industry global market size, regional shares, competitors with an insulin drugs market share, detailed insulin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the insulin drugs industry.
  • This insulin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE

Retrieved on: 
Wednesday, May 18, 2022

Cambridge, UK, 18 May 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing todays therapies to enable healthier lives, today announces that it will host a key opinion leader webinar entitled The Need for Concentrated and Rapid Acting Insulin Treatments in Diabetes Care, on Thursday 26 May, 2022, at 15:00-16:30 BST.

Key Points: 
  • Cambridge, UK, 18 May 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing todays therapies to enable healthier lives, today announces that it will host a key opinion leader webinar entitled The Need for Concentrated and Rapid Acting Insulin Treatments in Diabetes Care, on Thursday 26 May, 2022, at 15:00-16:30 BST.
  • While rapid acting insulins have become standard of care, there are currently no concentrated rapid acting insulin products available to patients to enable reduced injection volumes, fewer injections per day and the potential for improved blood glucose control.
  • Arecors webinar will bring together four world-class experts in the field of diabetes care, who will discuss the AT278 clinical data as well as the clinical and patient need.
  • Davida Kruger, Certified Diabetes Nurse Practitioner, Henry Ford Health System, Division of Endocrinology, Detroit, USA, will focus on the benefits of concentrated insulin from the patient perspective.